Form 4: ResMed Inc. Executive Michael J. Rider Sells Shares Under 10b5-1 Plan

Michael J. Rider, Global General Counsel of ResMed Inc., sold 64 shares of common stock at $234.1 per share on March 3, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 3, 2025, Michael J. Rider, the Global General Counsel of ResMed Inc., sold 64 shares of ResMed Common Stock.
• The sale was executed at a price of $234.1 per share.
• The transaction was conducted under a Rule 10b5-1 plan adopted on May 11, 2024.
• Following the transaction, Rider directly owns 8,910 shares of ResMed Common Stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an insider transaction. It doesn't convey any particularly positive or negative sentiment about the company's performance or prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The sale by the Global General Counsel is unlikely to have a significant impact on the company's stock price.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the impact is likely minimal given the small number of shares sold and the existence of a pre-arranged trading plan.

Key Dates